- Datum18.11.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
Repare Therapeutics Inc. Aktie
Verkaufen
Kaufen
Repare Therapeutics Inc. Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Repare Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
30,61 %
Intraday
25,29 %
1 Woche
17,76 %
1 Monat
64,50 %
Seit Jahresbeginn
-30,71 %
1 Jahr
-87,85 %
3 Jahre
-92,26 %
5 Jahre
Passender Service zu Repare Therapeutics Inc.
Webinar zu Repare Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,890-4,070
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Repare Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Repare Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
